| 04/15/2024 13:00 |
Notice Regarding Issuance of JPY Hybrid Bonds |
| 03/27/2024 08:00 |
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting |
| 02/09/2024 08:00 |
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of an Oral Orexin Agonist in Narcolepsy Type 1 in First Half of Fiscal Year 2024 |
| 02/02/2024 16:00 |
Quarterly Securities Report (The third quarter of 147th Business Term) for The Nine-month Period and Three-month Quarter Ended December 31, 2023 |
| 02/01/2024 15:30 |
Takeda Announces Chief Financial Officer Succession |
| 02/01/2024 15:00 |
Summary of Financial Statements for the Nine-month Period Ended December 31, 2023 (IFRS, Consolidated) |
| 01/15/2024 16:00 |
Announcement of a company split (simplified absorption-type company split/short-form company split) with a wholly-owned subsidiary |
| 12/14/2023 16:00 |
Corporate Governance Report 2023/12/14 |
| 11/30/2023 17:00 |
The 147th (interim period) Business Report |
| 11/10/2023 08:45 |
Takeda's ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of cTTP |
| 10/30/2023 16:00 |
Quarterly Securities Report (The second quarter of 147th Business Term) for The Six-month Period and Three-month Quarter Ended September 30, 2023 |
| 10/26/2023 15:00 |
Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS) |
| 10/26/2023 15:00 |
Summary of Financial Statements for the Six-month Period Ended September 30, 2023 (IFRS, Consolidated) |
| 10/18/2023 08:30 |
Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire |
| 10/02/2023 15:00 |
Takeda Announces Amendment of Compensation Recoupment Policy |
| 09/28/2023 08:45 |
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis |
| 09/11/2023 19:45 |
Positive Topline Results from Ph2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis |
| 08/01/2023 16:00 |
Quarterly Securities Report (The first quarter of 147th Business Term) for The Three-month Period Ended June 30, 2023 |
| 07/27/2023 15:00 |
Summary of Financial Statements for the Three-month Period Ended June 30, 2023 (IFRS, Consolidated) |
| 07/12/2023 15:45 |
Corporate Governance Report 2023/07/12 |
| 07/07/2023 00:30 |
2023 ANNUAL INTEGRATED REPORT |
| 06/28/2023 17:00 |
Annual Securities Report From April 1, 2022 to March 31, 2023 (The 146th Fiscal Year) |
| 06/23/2023 08:00 |
(Corrected) Notice of Convocation of the 147th Ordinary General Meeting of Shareholders and Meeting |
| 06/23/2023 08:00 |
Partial Correction to the Notice of Convocation of the 147th Ordinary General Meeting of Shareholders |
| 06/09/2023 16:00 |
Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Overseas |
| 06/01/2023 16:00 |
Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan |
| 05/31/2023 08:00 |
Message from Christophe Weber, President & CEO |
| 05/31/2023 08:00 |
Other items which are provided electronically for the 147th Ordinary General Meeting of Shareholders |
| 05/31/2023 08:00 |
Notice of Convocation of the 147th Ordinary General Meeting of Shareholders and Meeting Materials |
| 05/17/2023 10:00 |
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) |
| 05/11/2023 16:00 |
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2023 |
| 05/11/2023 15:00 |
Summary of Financial Statements for the Fiscal Year Ended March 31, 2023 (IFRS, Consolidated) |
